본문 바로가기
KERD
논문KCI 등재후보

Resistant hypertension: consensus document from the Korean society of hypertension

이해영|신진호|임상현|김광일|안신영|Lee Eun Mi|Kang Hee-Taik|Kim Hyeon Chang|Kim Hack-Lyoung|Cho Eun Joo|Kim Woohyeun|박성하|Lee Jang Hoon|Kim Ju Han|Lee Sunki|Park Jong-Moo
대한고혈압학회 (The Korean Society of Hypertension)|2023.01|Clinical Hypertension|제29권 |pp. 30-30|DOI 10.1186/s40885-023-00255-4

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

HypertensionAmbulatory blood pressure monitoringResistant hypertensionHome blood pressure monitoringRefractory hypertension

초록

Although reports vary, the prevalence of true resistant hypertension and apparent treatment-resistant hypertension (aTRH) has been reported to be 10.3% and 14.7%, respectively. As there is a rapid increase in the prevalence of obesity, chronic kidney disease, and diabetes mellitus, factors that are associated with resistant hypertension, the prevalence of resistant hypertension is expected to rise as well. Frequently, patients with aTRH have pseudoresistant hypertension [aTRH due to white-coat uncontrolled hypertension (WUCH), drug underdosing, poor adherence, and inaccurate office blood pressure (BP) measurements]. As the prevalence of WUCH is high among patients with aTRH, the use of out-of-office BP measurements, both ambulatory blood pressure monitoring (ABPM) and home blood pressure monitoring (HBPM), is essential to exclude WUCH. Non-adherence is especially problematic, and methods to assess adherence remain limited and often not clinically feasible. Therefore, the use of HBPM and higher utilization of singlepill fixed-dose combination treatments should be emphasized to improve drug adherence. In addition, primary aldosteronism and symptomatic obstructive sleep apnea are quite common in patients with hypertension and more so in patients with resistant hypertension. Screening for these diseases is essential, as the treatment of these secondary causes may help control BP in patients who are otherwise difficult to treat. Finally, a proper drug regimen combined with lifestyle modifications is essential to control BP in these patients.

Abstract

Although reports vary, the prevalence of true resistant hypertension and apparent treatment-resistant hypertension (aTRH) has been reported to be 10.3% and 14.7%, respectively. As there is a rapid increase in the prevalence of obesity, chronic kidney disease, and diabetes mellitus, factors that are associated with resistant hypertension, the prevalence of resistant hypertension is expected to rise as well. Frequently, patients with aTRH have pseudoresistant hypertension [aTRH due to white-coat uncontrolled hypertension (WUCH), drug underdosing, poor adherence, and inaccurate office blood pressure (BP) measurements]. As the prevalence of WUCH is high among patients with aTRH, the use of out-of-office BP measurements, both ambulatory blood pressure monitoring (ABPM) and home blood pressure monitoring (HBPM), is essential to exclude WUCH. Non-adherence is especially problematic, and methods to assess adherence remain limited and often not clinically feasible. Therefore, the use of HBPM and higher utilization of singlepill fixed-dose combination treatments should be emphasized to improve drug adherence. In addition, primary aldosteronism and symptomatic obstructive sleep apnea are quite common in patients with hypertension and more so in patients with resistant hypertension. Screening for these diseases is essential, as the treatment of these secondary causes may help control BP in patients who are otherwise difficult to treat. Finally, a proper drug regimen combined with lifestyle modifications is essential to control BP in these patients.

참고문헌 (163)

  1. Blood Pressure Lowering Treatment Trialists C, "Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure : an individual participant-level data meta-analysis", Lancet, 397(10285), pp.1625~1636 (2021)
  2. 김현창, "2018 Korean Society of Hypertension guidelines for the management of hypertension: part I-epidemiology of hypertension", Clinical Hypertension, 25(4), pp.45~50 (2019), 대한고혈압학회[DOI]
  3. 김현창, "Korea hypertension fact sheet 2018", Clinical Hypertension, 24(4), pp.11~14 (2018), 대한고혈압학회[DOI]
  4. Carey RM, "Resistant hypertension : detection, evaluation, and management : a scientific statement from the american heart association", Hypertension, 72(5), pp.e53~e90 (2018)
  5. Hae-Young Lee, "2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension", Clinical Hypertension, 25(4), pp.51~74 (2019), 대한고혈압학회[DOI]
  6. Calhoun DA, "Refractory hypertension : determination of prevalence, risk factors, and comorbidities in a large, population-based cohort", Hypertension, 63(3), pp.451~458 (2014)
  7. Calhoun DA, "Refractory and Resistant Hypertension: Antihypertensive Treatment Failure versus Treatment Resistance", Korean Circulation Journal, 46(5), pp.593~600 (2016), 대한심장학회
  8. 김학령, "The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension", Clinical Hypertension, 29, pp.11~11 (2023), 대한고혈압학회
  9. de la Sierra A, "Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring", Hypertension, 57(5), pp.898~902 (2011)
  10. Gupta P, "Biochemical screening for nonadherence is associated with blood pressure reduction and improvement in adherence", Hypertension, 70(5), pp.1042~1048 (2017)
  11. Noubiap JJ, "Global prevalence of resistant hypertension: a meta-analysis of data from 3.2million patients", Heart, 105(2), pp.98~105 (2019)
  12. Calhoun DA, "Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research", Hypertension, 51(6), pp.1403~1419 (2008)
  13. Weitzman D, "Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel", Hypertension, 64(3), pp.501~507 (2014)
  14. Choi SW, "Apparent treatment-resistant hypertension among elderly Korean hypertensives : an insight from the HIT registry", J Hum Hypertens, 28(3), pp.201~205 (2014)
  15. Lee KN, "Prevalence and characteristics of resistant hypertension at primary clinics in Korea : a nationwide cross-sectional study", Clin Hypertens, 22, pp.4~ (2015)
  16. Yoon M, "Prevalence and prognosis of refractory hypertension diagnosed using ambulatory blood pressure measurements", Hypertens Res, 45(8), pp.1353~1362 (2022)
  17. Narita K, "Association of treatment-resistant hypertension defined by home blood pressure monitoring with cardiovascular outcome", Hypertens Res, 45(1), pp.75~86 (2022)
  18. Daugherty SL, "Incidence and prognosis of resistant hypertension in hypertensive patients", Circulation, 125(13), pp.1635~1642 (2012)
  19. Muntner P, "Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease : results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial(ALLHAT)", Hypertension, 64(5), pp.1012~1021 (2014)
  20. Cardoso CRL, "Prognostic importance of on-treatment clinic and ambulatory blood pressures in resistant hypertension : A cohort study", Hypertension, 75(5), pp.1184~1194 (2020)
  21. Pickering TG, "Recommendations for blood pressure measurement in humans and experimental animals : part 1 : blood pressure measurement in humans : a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research", Circulation, 111(5), pp.697~716 (2005)
  22. Whelton PK, "2017 ACC", AHA, ABC, pp.ACPM, AGS[DOI]
  23. Egan BM, "Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network", Hypertension, 62(4), pp.691~697 (2013)
  24. Durand H, "Medication adherence among patients with apparent treatment-resistant hypertension : systematic review and meta-analysis", J Hypertens, 35(12), pp.2346~2357 (2017)
  25. Franklin SS, "The cardiovascular risk of white-coat hypertension", J Am Coll Cardiol, 68(19), pp.2033~2043 (2016)
  26. Landsberg L, "Obesity-related hypertension : pathogenesis, cardiovascular risk, and treatment : a position paper of The Obesity Society and the American Society of Hypertension", J Clin Hypertens(Greenwich), 15(1), pp.14~33 (2013)
  27. Hall JE, "Obesity-induced hypertension : interaction of neurohumoral and renal mechanisms", Circ Res, 116(6), pp.991~1006 (2015)
  28. Egan BM, "Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008", Circulation, 124(9), pp.1046~1058 (2011)
  29. Sacks FM, "Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group", N Engl J Med, 344(1), pp.3~10 (2001)
  30. Oh YS, "National heart, lung, and blood institute working group report on salt in human health and sickness : building on the current scientific evidence", Hypertension, 68(2), pp.281~288 (2016)
  31. Blaustein MP, "How NaCl raises blood pressure : a new paradigm for the pathogenesis of salt-dependent hypertension", Am J Physiol Heart Circ Physiol, 302(5), pp.H1031~1049 (2012)
  32. Pimenta E, "Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension : results from a randomized trial", Hypertension, 54(3), pp.475~481 (2009)
  33. Diaz KM, "Physical activity and the prevention of hypertension", Curr Hypertens Rep, 15(6), pp.659~668 (2013)
  34. Dimeo F, "Aerobic exercise reduces blood pressure in resistant hypertension", Hypertension, 60(3), pp.653~658 (2012)
  35. Puddey IB, "Alcohol is bad for blood pressure", Clin Exp Pharmacol Physiol, 33(9), pp.847~852 (2006)
  36. Miller PM, "Excessive alcohol consumption and hypertension : clinical implications of current research", J Clin Hypertens(Greenwich), 7(6), pp.346~351 (2005)
  37. Piano MR, "Impact of smokeless tobacco products on cardiovascular disease : implications for policy, prevention, and treatment : a policy statement from the American Heart Association", Circulation, 122(15), pp.1520~1544 (2010)
  38. Grossman A, "Drug induced hypertension–an unappreciated cause of secondary hypertension", Eur J Pharmacol, 763(Pt A), pp.15~22 (2015)
  39. Cohen JB, "Cancer therapy-related hypertension : A scientific statement From the American heart association", Hypertension, 80(3), pp.e46~57 (2023)
  40. Fay KS, "Resistant hypertension in people with CKD : a review", Am J Kidney Dis, 77(1), pp.110~121 (2021)
  41. Mann SJ, "Severe paroxysmal hypertension(pseudopheochromocytoma) : understanding the cause and treatment", Arch Intern Med, 159(7), pp.670~674 (1999)
  42. Jin P, "Quantification of respiration-induced esophageal tumor motion using fiducial markers and four-dimensional computed tomography", Radiother Oncol, 118(3), pp.492~497 (2016)
  43. Zhong X, "Increased sympathetic and decreased parasympathetic cardiovascular modulation in normal humans with acute sleep deprivation", J Appl Physiol(1985), 98(6), pp.2024~2032 (2005)
  44. Huan Y, "Chronic renal disease", pp.163~169 (2014), Academic Press
  45. Muntner P, "Hypertension awareness, treatment, and control in adults with CKD : results from the Chronic Renal Insufficiency Cohort(CRIC)Study", Am J Kidney Dis, 55(3), pp.441~451 (2010)
  46. Ihm Chun Gyoo, "Hypertension in Chronic Glomerulonephritis", Electrolytes & Blood Pressure, 13(2), pp.41~45 (2015), 전해질고혈압연구회[DOI]
  47. Orofino L, "Hypertension in primary chronic glomerulonephritis : analysis of 288biopsied patients", Nephron, 45(1), pp.22~26 (1987)
  48. Vaidya A, "The expanding spectrum of primary aldosteronism : implications for diagnosis, pathogenesis, and treatment", Endocr Rev, 39(6), pp.1057~1088 (2018)
  49. Calhoun DA, "Hyperaldosteronism among black and white subjects with resistant hypertension", Hypertension, 40(6), pp.892~896 (2002)
  50. Funder JW, "Case detection, diagnosis, and treatment of patients with primary aldosteronism : an endocrine society clinical practice guideline", J Clin Endocrinol Metab, 93(9), pp.3266~3281 (2008)
  51. Logan AG, "High prevalence of unrecognized sleep apnoea in drug-resistant hypertension", J Hypertens, 19(12), pp.2271~2277 (2001)
  52. Pimenta E, "Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism", Chest, 143(4), pp.978~983 (2013)
  53. Gonzaga CC, "Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension", J Clin Sleep Med, 6(4), pp.363~368 (2010)
  54. Friedman O, "Relationship between overnight rostral fluid shift and obstructive sleep apnea in drug-resistant hypertension", Hypertension, 56(6), pp.1077~1082 (2010)
  55. Kasai T, "Effect of intensified diuretic therapy on overnight rostral fluid shift and obstructive sleep apnoea in patients with uncontrolled hypertension", J Hypertens, 32(3), pp.673~680 (2014)
  56. Chung F, "STOP questionnaire : a tool to screen patients for obstructive sleep apnea", Anesthesiology, 108(5), pp.812~821 (2008)
  57. Herrmann SM, "Current concepts in the treatment of renovascular hypertension", Am J Hypertens, 31(2), pp.139~149 (2018)
  58. Anderson GH Jr, "The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients", J Hypertens, 12(5), pp.609~615 (1994)
  59. Martell N, "High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension", Blood Press, 12(3), pp.149~154 (2003)
  60. Lenders JW, "Pheochromocytoma and paraganglioma : an endocrine society clinical practice guideline", J Clin Endocrinol Metab, 99(6), pp.1915~1942 (2014)
  61. Lenders JW, "Phaeochromocytoma", Lancet, 366(9486), pp.665~675 (2005)
  62. Schwartz GL, "Screening for adrenal-endocrine hypertension : overview of accuracy and cost-effectiveness", Endocrinol Metab Clin North Am, 40(2), pp.279~294 vii (2011)
  63. Martins LC, "Prevalence and associated factors of subclinical hypercortisolism in patients with resistant hypertension", J Hypertens, 30(5), pp.967~973 (2012)
  64. Bhatt H, "Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement", J Am Soc Hypertens, 10(6), pp.493~499 (2016)
  65. de la Sierra A, "Clinical features of 8295patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring", Hypertension, 57, pp.898~902 (2011)
  66. 신진호, "Discordance between ambulatory versus clinic blood pressure according to global cardiovascular risk group", The Korean Journal of Internal Medicine, 30(5), pp.610~619 (2015), 대한내과학회[DOI]
  67. Brown MA, "Is resistant hypertension really resistant?", Am J Hypertens, 14(12), pp.1263~1269 (2001)
  68. Muxfeldt ES, "True resistant hypertension : is it possible to be recognized in the office?", Am J Hypertens, 18(12), pp.1534~1540 (2005)
  69. Verdecchia P, "Prognostic significance of the white coat effect", Hypertension, 29(6), pp.1218~1224 (1997)
  70. Eskås PA, "Adherence to medication and drug monitoring in apparent treatment-resistant hypertension", Blood Press, 25(4), pp.199~205 (2016)
  71. 민현진, "Clinical Features of Obstructive Sleep Apnea That Determine Its High Prevalence in Resistant Hypertension", Yonsei Medical Journal, 56(5), pp.1258~1265 (2015), 연세대학교의과대학[DOI]
  72. Yeghiazarians Y, "Obstructive sleep apnea and cardiovascular disease : A scientific statement from the american heart association", Circulation, 144(3), pp.e56~67 (2021)
  73. Pickering TG, "When and how to use self(home)and ambulatory blood pressure monitoring", J Am Soc Hypertens, 2(3), pp.119~124 (2008)
  74. 김혜미, "Role of home blood pressure monitoring in resistant hypertension", Clinical Hypertension, 29, pp.2~2 (2023), 대한고혈압학회[DOI]
  75. Schwartz GL, "Screening for primary aldosteronism in essential hypertension : diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity", Clin Chem, 51(2), pp.386~394 (2005)
  76. Nishizaka MK, "Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension", Am J Hypertens, 18(6), pp.805~812 (2005)
  77. Sawka AM, "A comparison of biochemical tests for pheochromocytoma : measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines", J Clin Endocrinol Metab, 88(2), pp.553~558 (2003)
  78. Choi KH, "Persistence with antihypertensives in uncomplicated treatment-naive very elderly patients : a nationwide population-based study", BMC Cardiovasc Disord, 17(1), pp.232~ (2017)
  79. Bourque G, "Nonadherence is common in patients with apparent resistant hypertension : a systematic review and meta-analysis", Am J Hypertens, 36(7), pp.394~403 (2023)
  80. Choudhry NK, "Medication adherence and blood pressure control : a scientific statement from the american heart association", Hypertension, 79(1), pp.e1~14 (2022)
  81. Osterberg L, "Adherence to medication", N Engl J Med, 353(5), pp.487~497 (2005)
  82. Lawson AJ, "Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals", J Hypertens, 38(6), pp.1165~1173 (2020)
  83. Jung O, "Resistant hypertension? Assessment of adherence by toxicological urine analysis", J Hypertens, 31(4), pp.766~774 (2013)
  84. Siddiqui M, "Antihypertensive medication adherence and confirmation of true refractory hypertension", Hypertension, 75(2), pp.510~515 (2020)
  85. Burnier M, "Measuring, analyzing, and managing drug adherence in resistant hypertension", Hypertension, 62(2), pp.218~225 (2013)
  86. Lane D, "Nonadherence in hypertension : How to develop and implement chemical adherence testing", Hypertension, 79(1), pp.12~23 (2022)
  87. Gupta P, "Risk factors for nonadherence to antihypertensive treatment", Hypertension, 69(6), pp.1113~1120 (2017)
  88. Reese PP, "Automated reminders and physician notification to promote immunosuppression adherence among kidney transplant recipients : a randomized trial", Am J Kidney Dis, 69(3), pp.400~409 (2017)
  89. Morawski K, "Association of a smartphone application with medication adherence and blood pressure control : the MedISAFE-BP randomized clinical trial", JAMA Intern Med, 178(6), pp.802~809 (2018)
  90. Jung SH, "Medication adherence improvement by using administration timing simplification protocol(ATSP)in cardiovascular disease patients", J Atheroscler Thromb, 24(8), pp.841~852 (2017)
  91. Williams B, "2018 ESC", ESH Guidelines for the management of arterial hypertension, 2018, pp.39(33), 3021~3104
  92. Weinberger MH, "Salt sensitivity of blood pressure in humans", Hypertension, 27(3 Pt 2), pp.481~490 (1996)
  93. Strazzullo P, "Salt intake, stroke, and cardiovascular disease : meta-analysis of prospective studies", Bmj, 339, pp.b4567~ (2009)
  94. Elijovich F, "Salt sensitivity of blood pressure : a scientific statement from the american heart association", Hypertension, 68(3), pp.e7~46 (2016)
  95. Balafa O, "Salt sensitivity and hypertension", J Hum Hypertens, 35(3), pp.184~192 (2021)
  96. Appel LJ, "A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group", N Engl J Med, 336(16), pp.1117~1124 (1997)
  97. Carnethon MR, "Joint associations of physical activity and aerobic fitness on the development of incident hypertension : coronary artery risk development in young adults", Hypertension, 56(1), pp.49~55 (2010)
  98. Arroll B, "Does physical activity lower blood pressure : a critical review of the clinical trials", J Clin Epidemiol, 45(5), pp.439~447 (1992)
  99. Cornelissen VA, "Exercise training for blood pressure : a systematic review and meta-analysis", J Am Heart Assoc, 2(1), pp.e004473~ (2013)
  100. Rossi A, "The impact of physical activity on mortality in patients with high blood pressure : a systematic review", J Hypertens, 30(7), pp.1277~1288 (2012)
  101. Guimarães GV, "Effects of short-term heated water-based exercise training on systemic blood pressure in patients with resistant hypertension : a pilot study", Blood Press Monit, 18(6), pp.342~345 (2013)
  102. Lopes S, "Aerobic exercise improves central blood pressure and blood pressure variability among patients with resistant hypertension : results of the EnRicH trial", Hyperten Res, 46, pp.1547~1557 (2023)
  103. Piepoli MF, "2016 European Guidelines on cardiovascular disease prevention in clinical practice : The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice(constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation(EACPR)", Eur Heart J, 37(29), pp.2315~2381 (2016)
  104. Yun Jun Yang, "An Overview of Current Physical Activity Recommendations in Primary Care", Korean Journal of Family Medicine, 40(3), pp.135~142 (2019), 대한가정의학회[DOI]
  105. Ahmed SB, "Body mass index and angiotensin-dependent control of the renal circulation in healthy humans", Hypertension, 46(6), pp.1316~1320 (2005)
  106. Zhai F, "Closing the energy gap to prevent weight gain in China", Obes Rev, 9(Suppl 1), pp.107~112 (2008)
  107. Mozaffarian D, "Changes in diet and lifestyle and long-term weight gain in women and men", N Engl J Med, 364(25), pp.2392~2404 (2011)
  108. Neter JE, "Influence of weight reduction on blood pressure : a meta-analysis of randomized controlled trials", Hypertension, 42(5), pp.878~884 (2003)
  109. Aucott L, "Effects of weight loss in overweight", obese individuals and long-term hypertension outcomes : a systematic review, 2005, pp.45(6), 1035~1041
  110. Siebenhofer A, "Long-term effects of weight-reducing diets in hypertensive patients", Cochrane Database Syst Rev, (9), pp.Cd008274~ (2011)
  111. Rimm EB, "Moderate alcohol intake and lower risk of coronary heart disease : meta-analysis of effects on lipids and haemostatic factors", Bmj, 319(7224), pp.1523~1528 (1999)
  112. Mukamal KJ, "Alcohol consumption and cardiovascular mortality among U.S. adults, 1987 to 2002", J Am Coll Cardiol, 55(13), pp.1328~1335 (2010)
  113. Xin X, "Effects of alcohol reduction on blood pressure : a meta-analysis of randomized controlled trials", Hypertension, 38(5), pp.1112~1117 (2001)
  114. Roerecke M, "The effect of a reduction in alcohol consumption on blood pressure : a systematic review and meta-analysis", Lancet Public Health, 2(2), pp.e108~120 (2017)
  115. Dickinson HO, "Lifestyle interventions to reduce raised blood pressure : a systematic review of randomized controlled trials", J Hypertens, 24(2), pp.215~233 (2006)
  116. "What Is a standard drink?" (2018)[URL]
  117. Primatesta P, "Association between smoking and blood pressure : evidence from the health survey for England", Hypertension, 37(2), pp.187~193 (2001)
  118. Cohen DL, "Does cigarette use modify blood pressure measurement or the effectiveness of blood pressure medications?", J Clin Hypertens(Greenwich), 11(11), pp.657~658 (2009)
  119. Li G, "The association between smoking and blood pressure in men : a cross-sectional study", BMC Public Health, 17(1), pp.797~ (2017)
  120. Sahle BW, "Weight gain after smoking cessation and risk of major chronic diseases and mortality", JAMA Netw Open, 4(4), pp.e217044~ (2021)
  121. Lim SS, "A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010 : a systematic analysis for the Global Burden of Disease Study 2010", Lancet, 380(9859), pp.2224~2260 (2012)
  122. Roush GC, "Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone : antihypertensive and metabolic effects", Hypertension, 65(5), pp.1041~1046 (2015)
  123. Cirillo M, "Parallel-group 8-week study on chlorthalidone effects in hypertensives with low kidney function", Hypertension, 63(4), pp.692~697 (2014)
  124. Agarwal R, "Chlorthalidone for hypertension in advanced chronic kidney disease", N Engl J Med, 385(27), pp.2507~2519 (2021)
  125. Rossignol P, "The double challenge of resistant hypertension and chronic kidney disease", Lancet, 386(10003), pp.1588~1598 (2015)
  126. Tamargo J, "Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents", Expert Opin Pharmacother, 15(5), pp.605~621 (2014)
  127. Williams B, "Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension(PATHWAY-2) : a randomised, double-blind, crossover trial", Lancet, 386(10008), pp.2059~2068 (2015)
  128. Williams B, "Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride : the PATHWAY-2 mechanisms substudies", Lancet Diabetes Endocrinol, 6(6), pp.464~475 (2018)
  129. Agarwal R, "Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease(AMBER) : a phase 2, randomised, double-blind, placebo-controlled trial", Lancet, 394(10208), pp.1540~1550 (2019)
  130. Agarwal R, "A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease", Clin Kidney J, 16(2), pp.293~302 (2023)
  131. 이주희, "Current status and therapeutic considerations of hypertension in the elderly", The Korean Journal of Internal Medicine, 34(4), pp.687~695 (2019), 대한내과학회[DOI]
  132. Parati G, "The human sympathetic nervous system : its relevance in hypertension and heart failure", Eur Heart J, 33(9), pp.1058~1066 (2012)
  133. Evelyn KA, "Effect of sympathectomy on blood pressure in hypertension; a review of 13 years’ experience of the Massachusetts General Hospital", J Am Med Assoc, 140(7), pp.592~602 (1949)
  134. Krum H, "Percutaneous renal denervation in patients with treatment-resistant hypertension : final 3-year report of the Symplicity HTN-1 study", Lancet, 383(9917), pp.622~629 (2014)
  135. Esler MD, "Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension : 36 month results from the SYMPLICITY HTN-2 randomized clinical trial", Eur Heart J, 35(26), pp.1752~1759 (2014)
  136. Bhatt DL, "A controlled trial of renal denervation for resistant hypertension", N Engl J Med, 370(15), pp.1393~1401 (2014)
  137. Townsend RR, "Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications(SPYRAL HTN-OFF MED) : a randomised, sham-controlled, proof-of-concept trial", Lancet, 390(10108), pp.2160~2170 (2017)
  138. Azizi M, "Endovascular ultrasound renal denervation to treat hypertension(RADIANCE-HTN SOLO) : a multicentre, international, single-blind, randomised, sham-controlled trial", Lancet, 391(10137), pp.2335~2345 (2018)
  139. Azizi M, "Endovascular ultrasound renal denervation to treat hypertension : The RADIANCE II randomized clinical trial", Jama, 329(8), pp.651~661 (2023)
  140. Schmieder RE, "European Society of Hypertension position paper on renal denervation 2021", J Hypertens, 39(9), pp.1733~1741 (2021)
  141. Azizi M, "Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension(DENERHTN) : a multicentre, open-label, randomised controlled trial", Lancet, 385(9981), pp.1957~1965 (2015)
  142. Kandzari DE, "Effect of renal denervation on blood pressure in the presence of antihypertensive drugs : 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial", Lancet, 391(10137), pp.2346~2355 (2018)
  143. Azizi M, "Ultrasound renal denervation for hypertension resistant to a triple medication pill(RADIANCE-HTN TRIO) : a randomised, multicentre, single-blind, shamcontrolled trial", Lancet, 397(10293), pp.2476~2486 (2021)
  144. Mahfoud F, "Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs(SPYRAL HTN-ON MED) : a randomised, sham-controlled trial", Lancet, 399(10333), pp.1401~1410 (2022)
  145. Mancia G, "2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association(ERA)and the International Society of Hypertension(ISH)", J Hypertens (2023)
  146. Heusser K, "Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients", Hypertension, 55(3), pp.619~626 (2010)
  147. Bisognano JD, "Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension : results from the double-blind, randomized, placebo-controlled rheos pivotal trial", J Am Coll Cardiol, 58(7), pp.765~773 (2011)
  148. Hoppe UC, "Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile : results from the Barostim neo trial", J Am Soc Hypertens, 6(4), pp.270~276 (2012)
  149. Wallbach M, "Long-term effects of baroreflex activation therapy : 2-year follow-up data of the BAT Neo system", Clin Res Cardiol, 109(4), pp.513~522 (2020)
  150. Peter DA, "Fluid structure interaction with contact surface methodology for evaluation of endovascular carotid implants for drug-resistant hypertension treatment", J Biomech Eng, 134(4), pp.041001~ (2012)
  151. Spiering W, "Endovascular baroreflex amplification for resistant hypertension : a safety and proof-of-principle clinical study", Lancet, 390(10113), pp.2655~2661 (2017)
  152. van Kleef M, "Treatment of resistant hypertension with endovascular baroreflex amplification : 3-year results from the CALM-FIM study", JACC Cardiovasc Interv, 15(3), pp.321~332 (2022)
  153. Mahfoud F, "Proceedings from the 3rd European clinical consensus conference for clinical trials in device-based hypertension therapies", Eur Heart J, 41(16), pp.1588~1599 (2020)
  154. Hoshide S, "Characteristics of hypertension in obstructive sleep apnea : An Asian experience", J Clin Hypertens(Greenwich), 23(3), pp.489~495 (2021)
  155. Parati G, "Obstructive sleep apnea syndrome as a cause of resistant hypertension", Hypertens Res, 37(7), pp.601~613 (2014)
  156. Chiu KL, "Fluid shift by lower body positive pressure increases pharyngeal resistance in healthy subjects", Am J Respir Crit Care Med, 174(12), pp.1378~1383 (2006)
  157. Martínez-García MA, "Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension : the HIPARCO randomized clinical trial", Jama, 310(22), pp.2407~2415 (2013)
  158. Becker HF, "Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea", Circulation, 107(1), pp.68~73 (2003)
  159. Sapiña-Beltrán E, "Effect of CPAP treatment on BP in resistant hypertensive patients according to the BP dipping pattern and the presence of nocturnal hypertension", Hypertens Res, 45(3), pp.436~444 (2022)
  160. Dudenbostel T, "Refractory hypertension : a novel phenotype of antihypertensive treatment failure", Hypertension, 67(6), pp.1085~1092 (2016)
  161. Cardoso CRL, "Refractory Hypertension and risks of adverse cardiovascular events and mortality in patients with resistant hypertension : a prospective cohort study", J Am Heart Assoc, 9(17), pp.e017634~ (2020)
  162. Velasco A, "Refractory hypertension is not attributable to intravascular fluid retention as determined by intracardiac volumes", Hypertension, 72(2), pp.343~349 (2018)
  163. Salvador VD, "Novel antihypertensive agents for resistant hypertension: what does the future hold?", Hypertens Res (2022)

관련 논문AI추천

Apparent treatment-resistant hypertension among ambulatory hypertensive patients: a cross-sectional study from 13 general hospitals조상호, Bong-Ryeol Lee, Byung-Su Yoo, Choong Hwan Kwak, Dong-Ju Choi, Hae-Young Lee, Jinho Shin, Jin Joo Park, Joong-Wha Chung, Mi-Seung Shin, Sang Hyun Kim, Sehun Kim, Seok-Min Kang, Si Wan Choi, Sung-Ji Park대한내과학회 · The Korean Journal of Internal Medicine2021 · 제36권 제4호Role of home blood pressure monitoring in resistant hypertension김혜미, 신진호대한고혈압학회 · Clinical Hypertension2023 · 제29권 Clinical features and predictors of masked uncontrolled hypertension from the Korean Ambulatory Blood Pressure Monitoring Registry김우식, Eun Mi Lee, Hyun-Jin Kim, Jeong-Hun Shin, Jinho Shin, Ju Han Kim, Sang Hyun Ihm, Sang Jae Rhee, Sungha Park, Sun Ho Hwang, Wook Bum Pyun, Yonggu Lee대한내과학회 · The Korean Journal of Internal Medicine2021 · 제36권 제5호Analysis of Medication Adherence and Influencing Factors in Patients With Treatment-Resistant Hypertension in South Korea: A Nationwide Retrospective Cohort Study강혜영, 안현수, 유윤미, 이한길한국보건의료기술평가학회 · 보건의료기술평가2025 · 제13권 제2호When and how to use ambulatory blood pressure monitoring and home blood pressure monitoring for managing hypertensionLee Eun Mi대한고혈압학회 · Clinical Hypertension2024 · 제30권 Home blood pressure monitoring: a position statement from the Korean Society of Hypertension Home Blood Pressure Forum김광일, 김주한, 김철호, 박성하, 박재형, 신진호, 이은미, 이해영, 임상현, Kim Jang Young대한고혈압학회 · Clinical Hypertension2022 · 제28권

이 간행물의 다른 논문 (32건)

Withdrawal of antihypertensaive medication in young to middle-aged adults: a prospective, single-group, intervention study이해영, 이경숙pp. 1-1Role of home blood pressure monitoring in resistant hypertension김혜미, 신진호pp. 2-2Ideal cardiovascular health metrics and the risk of nonalcoholic fatty liver disease in Korean adultsJung Sun Jae, Kim Seung Up, 김현창, 심선영pp. 3-3The association between carbon and nitrogen stable isotope ratios of human hair and hypertensionJong‑Ku Park, 안성복pp. 4-4Fok I and Bsm I gene polymorphism of vitamin D receptor and essential hypertension: a mechanistic linkRajesh Kumar Khare, Priyanka Thapa Manger, Richa Awasthipp. 5-5
원문 보기